Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: BDC-1001|DRUG: Pertuzumab
Sponsor: Bolt Biotherapeutics, Inc.
Collaborators: Hoffmann-La Roche